These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2978259)

  • 1. [Study on short-term clinical trial of R-77-3 [3-(4-cyclo-pentyl-l-piperazinyl) imino methyl rifamycin SV] by mouse foot-pad technique].
    Wang HY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1988 Oct; 10(5):374-5. PubMed ID: 2978259
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473.
    Ji BH; Chen JK; Lu XZ; Wang SY; Ni GX; Hou YH; Zhou DH; Tang QK
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):563-77. PubMed ID: 3546547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
    Dhople AM; Ibanez MA
    Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy.
    Levy L
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4 Suppl):823-9. PubMed ID: 3325574
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM; Dimova V
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of sulphone resistant leprosy--a review of sixty one cases.
    Seshadri PS; Ravi NT
    Lepr India; 1982 Oct; 54(4):639-47. PubMed ID: 6191123
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
    Dhople AM
    Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mouse foot-pad technique for cultivation of Mycobacterium leprae.
    Levy L; Ji B
    Lepr Rev; 2006 Mar; 77(1):5-24. PubMed ID: 16715686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer drugs in leprosy.
    Grosset JH
    Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of drugs for activity against Mycobacterium leprae.
    Baohong J; Matsuo Y; Colston MJ
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4 Suppl):836-42. PubMed ID: 3325576
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment failure in leprosy.
    Levy L
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):177-82. PubMed ID: 776854
    [No Abstract]   [Full Text] [Related]  

  • 12. Mouse foot-pad studies with M. leprae--effect of desoxy fructo serotonin (DFS) and related compounds.
    Balakrishnan S; Mester L; Venkataramaniah HN; Bhatia VN
    Indian J Lepr; 1985; 57(2):323-8. PubMed ID: 3908578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifampicin resistant leprosy: a review and a research proposal of a pilot study.
    Ji B
    Lepr Rev; 2002 Mar; 73(1):2-8. PubMed ID: 11969122
    [No Abstract]   [Full Text] [Related]  

  • 14. Activity of two doses of rifampin against Mycobacterium leprae.
    Husser JA; Traore I; Daumerie D
    Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):359-64. PubMed ID: 7963907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How should leprosy be treated?].
    Mahé A
    Ann Dermatol Venereol; 1998 Dec; 125(12):881-3. PubMed ID: 9922859
    [No Abstract]   [Full Text] [Related]  

  • 16. Concepts behind the development of multiple drug therapy regimens in leprosy.
    Waters MF
    Lepr Rev; 1986 Dec; 57 Suppl 1():61-7. PubMed ID: 3295437
    [No Abstract]   [Full Text] [Related]  

  • 17. Superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor a clinical trial in lepromatous leprosy of the two regimens of rifampin and dapsone.
    Gelber RH; Humphres RC; Fieldsteel AH
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):273-83. PubMed ID: 3522770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Search for newer antileprosy drugs.
    Dhople AM
    Indian J Lepr; 2000; 72(1):5-20. PubMed ID: 10935183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum inhibitory and bactericidal dosages of rifampici against Mycobacterium leprae in the mouse foot pad: relationship to serum rifampicin concentrations.
    Holmes IB
    Int J Lepr Other Mycobact Dis; 1974; 42(3):289-96. PubMed ID: 4617716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.